Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Gap Down – Time to Sell?

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF)’s stock price gapped down before the market opened on Monday . The stock had previously closed at $22.2775, but opened at $21.11. Hikma Pharmaceuticals shares last traded at $21.10, with a volume of 22,673 shares trading hands.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Citigroup reissued a “buy” rating on shares of Hikma Pharmaceuticals in a research note on Wednesday, August 12th. Barclays raised shares of Hikma Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 8th. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Hikma Pharmaceuticals has a consensus rating of “Moderate Buy”.

Hikma Pharmaceuticals Price Performance

The company has a quick ratio of 1.06, a current ratio of 1.82 and a debt-to-equity ratio of 0.57. The business’s 50 day moving average price is $21.80 and its 200 day moving average price is $19.72.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals plc is a multinational pharmaceutical company that develops, manufactures and markets a broad portfolio of medicines. Its products include generic and specialty pharmaceuticals, injectable medicines, and branded treatments across a range of therapeutic areas.

The company operates through three principal businesses: Injectables, which supplies hospital and clinical medicines; Generics, which offers off-patent prescription products, primarily in the United States; and Branded, which markets medicines under established brand names across the Middle East and North Africa.